Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview

about

Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview

Item

http://www.wikidata.org/entity/Q37229148

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview

@en

Bendamustine

@nl

type

Item

label

Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview

@en

Bendamustine

@nl

prefLabel

Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview

@en

Bendamustine

@nl

P1476

Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overview

@en

P2093

Hoyee Leong

http://www.w3.org/2001/XMLSchema#string

Mary Ellen Bonk

http://www.w3.org/2001/XMLSchema#string

P2860

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Bendamustine.

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).

Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.

P304

73-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19561839

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

2697069

http://www.w3.org/2001/XMLSchema#string